Participants Receiving Dehydroepiandrosterone during Treatment for Cocaine Dependence Show High Rates of Cocaine Use in a Placebo-Controlled Pilot Study

Steve Shoptaw, Jeffery Wilkins, Geoffrey Twitchell, Maria Dorota Majewska, Xiaowei Yang, Walter Ling

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Twenty-three cocaine-dependent participants were randomly assigned to receive either dehydroepiandrosterone (DHEA; n = 11; 100 mg/day) or placebo (n = 12) in the context of 12 weeks of thrice weekly cognitive-behavioral group counseling. Outcomes were retention, urine drug screening, cocaine craving, adverse experiences, and medication compliance. DHEA-treated participants averaged 45.8 (SD = 28.8) days in treatment, compared with 70.7 (SD = 20.6) days for placebo, t(21) = -2.4, p = .03, and provided 26.8% (SD = 29.3) of urine samples free of cocaine metabolite compared with 70.6% (SD = 39.9) for the placebo condition, t(21) = -3.0, p = .01. No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence.

Original languageEnglish (US)
Pages (from-to)126-135
Number of pages10
JournalExperimental and Clinical Psychopharmacology
Volume12
Issue number2
DOIs
StatePublished - May 2004

Fingerprint

Cocaine-Related Disorders
Dehydroepiandrosterone
Cocaine
Placebos
Medication Adherence
Urine
Preclinical Drug Evaluations
Therapeutics
Counseling
Drug Therapy
Craving

ASJC Scopus subject areas

  • Pharmacology
  • Experimental and Cognitive Psychology

Cite this

Participants Receiving Dehydroepiandrosterone during Treatment for Cocaine Dependence Show High Rates of Cocaine Use in a Placebo-Controlled Pilot Study. / Shoptaw, Steve; Wilkins, Jeffery; Twitchell, Geoffrey; Majewska, Maria Dorota; Yang, Xiaowei; Ling, Walter.

In: Experimental and Clinical Psychopharmacology, Vol. 12, No. 2, 05.2004, p. 126-135.

Research output: Contribution to journalArticle

Shoptaw, Steve ; Wilkins, Jeffery ; Twitchell, Geoffrey ; Majewska, Maria Dorota ; Yang, Xiaowei ; Ling, Walter. / Participants Receiving Dehydroepiandrosterone during Treatment for Cocaine Dependence Show High Rates of Cocaine Use in a Placebo-Controlled Pilot Study. In: Experimental and Clinical Psychopharmacology. 2004 ; Vol. 12, No. 2. pp. 126-135.
@article{b8b50e90c1164177b73f2f3a5a89faf9,
title = "Participants Receiving Dehydroepiandrosterone during Treatment for Cocaine Dependence Show High Rates of Cocaine Use in a Placebo-Controlled Pilot Study",
abstract = "Twenty-three cocaine-dependent participants were randomly assigned to receive either dehydroepiandrosterone (DHEA; n = 11; 100 mg/day) or placebo (n = 12) in the context of 12 weeks of thrice weekly cognitive-behavioral group counseling. Outcomes were retention, urine drug screening, cocaine craving, adverse experiences, and medication compliance. DHEA-treated participants averaged 45.8 (SD = 28.8) days in treatment, compared with 70.7 (SD = 20.6) days for placebo, t(21) = -2.4, p = .03, and provided 26.8{\%} (SD = 29.3) of urine samples free of cocaine metabolite compared with 70.6{\%} (SD = 39.9) for the placebo condition, t(21) = -3.0, p = .01. No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence.",
author = "Steve Shoptaw and Jeffery Wilkins and Geoffrey Twitchell and Majewska, {Maria Dorota} and Xiaowei Yang and Walter Ling",
year = "2004",
month = "5",
doi = "10.1037/1064-1297.12.2.126",
language = "English (US)",
volume = "12",
pages = "126--135",
journal = "Experimental and Clinical Psychopharmacology",
issn = "1064-1297",
publisher = "American Psychological Association Inc.",
number = "2",

}

TY - JOUR

T1 - Participants Receiving Dehydroepiandrosterone during Treatment for Cocaine Dependence Show High Rates of Cocaine Use in a Placebo-Controlled Pilot Study

AU - Shoptaw, Steve

AU - Wilkins, Jeffery

AU - Twitchell, Geoffrey

AU - Majewska, Maria Dorota

AU - Yang, Xiaowei

AU - Ling, Walter

PY - 2004/5

Y1 - 2004/5

N2 - Twenty-three cocaine-dependent participants were randomly assigned to receive either dehydroepiandrosterone (DHEA; n = 11; 100 mg/day) or placebo (n = 12) in the context of 12 weeks of thrice weekly cognitive-behavioral group counseling. Outcomes were retention, urine drug screening, cocaine craving, adverse experiences, and medication compliance. DHEA-treated participants averaged 45.8 (SD = 28.8) days in treatment, compared with 70.7 (SD = 20.6) days for placebo, t(21) = -2.4, p = .03, and provided 26.8% (SD = 29.3) of urine samples free of cocaine metabolite compared with 70.6% (SD = 39.9) for the placebo condition, t(21) = -3.0, p = .01. No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence.

AB - Twenty-three cocaine-dependent participants were randomly assigned to receive either dehydroepiandrosterone (DHEA; n = 11; 100 mg/day) or placebo (n = 12) in the context of 12 weeks of thrice weekly cognitive-behavioral group counseling. Outcomes were retention, urine drug screening, cocaine craving, adverse experiences, and medication compliance. DHEA-treated participants averaged 45.8 (SD = 28.8) days in treatment, compared with 70.7 (SD = 20.6) days for placebo, t(21) = -2.4, p = .03, and provided 26.8% (SD = 29.3) of urine samples free of cocaine metabolite compared with 70.6% (SD = 39.9) for the placebo condition, t(21) = -3.0, p = .01. No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence.

UR - http://www.scopus.com/inward/record.url?scp=2342421523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342421523&partnerID=8YFLogxK

U2 - 10.1037/1064-1297.12.2.126

DO - 10.1037/1064-1297.12.2.126

M3 - Article

VL - 12

SP - 126

EP - 135

JO - Experimental and Clinical Psychopharmacology

JF - Experimental and Clinical Psychopharmacology

SN - 1064-1297

IS - 2

ER -